Verastem (VSTM) Projected to Post Earnings on Thursday

Verastem (NASDAQ:VSTM) is anticipated to announce its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to announce earnings of ($0.4730) per share and revenue of $26.57 million for the quarter. Individuals can check the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Verastem (NASDAQ:VSTM) last announced its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.08. The company had revenue of $40.08 million during the quarter, compared to analysts’ expectations of $22.88 million. Verastem had a negative net margin of 231.59% and a negative return on equity of 467.49%. On average, analysts expect Verastem to post ($1.51) EPS for the current fiscal year and ($1.24) EPS for the next fiscal year.

Verastem Price Performance

NASDAQ:VSTM opened at $9.59 on Tuesday. The company has a 50-day moving average of $8.21 and a 200-day moving average of $6.19. The company has a market capitalization of $868.47 million, a price-to-earnings ratio of -3.61 and a beta of 0.39. Verastem has a 52 week low of $3.43 and a 52 week high of $10.82. The company has a debt-to-equity ratio of 1.48, a quick ratio of 2.22 and a current ratio of 2.25.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Weiss Ratings cut shares of Verastem from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, October 15th. Citigroup reissued a “buy” rating on shares of Verastem in a research report on Thursday, October 8th. Benchmark restated a “buy” rating on shares of Verastem in a research note on Friday, October 16th. BTIG Research lifted their price objective on Verastem from $18.00 to $24.00 and gave the company a “buy” rating in a report on Thursday, October 15th. Finally, Alliance Global Partners reaffirmed a “buy” rating on shares of Verastem in a report on Thursday, October 15th. Eleven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $16.67.

Insider Transactions at Verastem

In other Verastem news, CEO Dan Paterson sold 44,121 shares of Verastem stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $8.00, for a total transaction of $352,968.00. Following the completion of the transaction, the chief executive officer directly owned 652,712 shares of the company’s stock, valued at approximately $5,221,696. This trade represents a 6.33% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 46,742 shares of company stock worth $373,920 in the last three months. Corporate insiders own 1.94% of the company’s stock.

Verastem Company Profile

Verastem, operating as Verastem Oncology, is a biopharmaceutical company focused on developing and commercializing targeted therapies for cancer. The company’s research is centered on tumors driven by abnormalities in the RAS/MAPK signaling pathway, which can promote cancer-cell growth and resistance to treatment.

Verastem’s leading product candidates include avutometinib, an oral RAF/MEK clamp designed to inhibit signaling within the RAS/MAPK pathway, and defactinib, an oral focal adhesion kinase inhibitor.